1. Scrip
  2. >>Archive

Profile: Cipla's Hamied On Cambridge, O-Levels And Sticking It Out

 
• By Anju Ghangurde

Cipla's journey over the years is steeped in history. Chairman Yusuf Hamied recalls growing up in the midst of leaders of India's freedom struggle, including Sarojini Naidu who became president of the Indian National Congress, Zakir Husain (who became the President of India), BG Kher (chief minister of Bombay) and Sardar Patel (India's first home minister and deputy prime minister), among others. Hamied's father and Cipla's founder, K A Hamied, supported Mahatma Gandhi's Non-Co-operation Movement against British rule. When Gandhi visited Cipla in 1939 he was said to have urged the company to supply medicines for the Indo-British war effort. Yusuf Hamied's mother was Jewish and his grandparents were killed in the Holocaust. In a candid interaction with Scrip's Anju Ghangurde in Mumbai as part of our ongoing executive profile series, Hamied recounts the influence of the late Lord (Alexander) Todd, Nobel Laureate and master of Christ's College, Cambridge, on his life; how he nearly packed up and left India between the 60s and the early 70s; and his views on religion.

Cipla's journey over the years is steeped in history. Chairman Yusuf Hamied recalls growing up in the midst of leaders of India's freedom struggle, including Sarojini Naidu who became president of the Indian National Congress, Zakir Husain (who became the President of India), BG Kher (chief minister of Bombay) and Sardar Patel (India's first home minister and deputy prime minister), among others. Hamied's father and Cipla's founder, K A Hamied, supported Mahatma Gandhi's Non-Co-operation Movement against British rule. When Gandhi visited Cipla in 1939 he was said to have urged the company to supply medicines for the Indo-British war effort. Yusuf Hamied's mother was Jewish and his grandparents were killed in the Holocaust. In a candid interaction with Scrip's Anju Ghangurde in Mumbai as part of our ongoing executive profile series, Hamied recounts the influence of the late Lord (Alexander) Todd, Nobel Laureate and master of Christ's College, Cambridge, on his life; how he nearly packed up and left India between the 60s and the early 70s; and his views on religion.

Yusuf Hamied, chairman of Cipla

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.